Anti-Diabetic drug, Lobeglitazone gets the DCGI nod!!

7 Feb 2023 • For type 2 diabetics who secrete insulin but have inadequate insulin sensitivity in their organs, limiting their ability to use insulin, the medication lobeglitazone has been developed. Lobeglitazone is a one-of-a-kind medication which has a relatively low risk of hypoglycemia.  Over 1 in 12 persons in India have diabetes, according to new statistics issued by the International Diabetes Federation. The unique formulation was created to reduce insulin resistance rather than compel its production from the pancreas. India has 74 million diabetics, which is the second-highest number in the world (after China) (141 million). In India, there are more than 50 percent of diabetics who are undiagnosed. In India, there are an additional 40 million persons who have impaired glucose tolerance, which puts them at a high risk of becoming type 2 diabetes. The drug has been shown to lower haemoglobin A1C (HbA1C) levels, lower blood sugar levels, and improve lipid and liver profiles. A film-coated tablet of lobeglitazone contains lobeglitazone sulphate, which is 0.5 mg of lobeglitazone. It has been given the go-ahead by Drugs Controller-General of India and offers a number of benefits, including increased pancreatic beta-cell activity, a higher safety profile, more effectiveness at lower dosages, and a lower risk of hypoglycemia, among others. It is a safe and well-tolerated formulation that offers repose to diabetic patients.

Source: Medical Dialogues| Read full story

Contact us

+91 9023-729662

Medflix Logo

© 2022 Plexus Professionals Network Pvt Ltd